保险公司与医院的搏弈规则

美国的医疗服务体系是建立在自由市场的基础上的。除凯撒(kaiser Permanente)医疗系统及一些联邦和地方政府拥有的医院之外,绝大多数医院是通过与不同的医疗保险公司签订合同,并依据合同来为这些保险公司的投保人提供医疗服务并获取报偿。由于每家医院的收费标准不一以及医疗保险公司采用的给付方法的不同,医疗保险公司与医院之间的合同谈判对双方来说都     

分析供电异常损坏医疗设备的原因及简便预防措施

目的本文分析了供电异常损坏医疗设备的原因,并提出了防止供电异常损坏医疗设备的简便措施,解决常见的因供电异常而损坏的医疗设备的问题。方法通过医疗设备维修实践,查找原因、总结经验的方法。结果从常见的四种机制出发,能够在较大程度上预防和检修医疗设备因供电原因而造成的损坏。结论提高医疗设备的供电监控措施,从常见的四种原因入手,可以预防医疗设备的损坏。     

对高职生诊断教学的几点思考

诊断学是论述诊断疾病的基本理论、基本技能和临床思雏方法的一门学科。现存的高职诊断学教学中存在培养目标不明确、课程设王不舍理、教学模式陈旧单一、实习基地建设不足、考试评估体系不完善等问题。为此，我们可以采取明确培养目标；调整课程设置，增加实践教学；采用多种教学模式；加强实习基地的建设；改进测评手段。强化技能训练等措施加以改进。     

酸相关性疾病与幽门螺杆菌感染

酸相关性疾病是指一类与胃酸攻击作用密切相关的上胃肠道疾病,包括器质性疾病和功能性疾病。根据病理生理机制的不同,酸相关性疾病主要分为胃食管反流病(GERD)、消化性溃疡病(PUD)和功能性消化不良(FD)三类。尽管目前对酸相关性疾病的发病机制已有了较深入的了解,但幽门螺杆菌(Hp)与其症状之间的关系仍不明确。现简要介绍幽门螺杆菌(Hp)感染在酸相关性疾病发生机制中的作用。     

BDNF is involved in sympathetic sprouting in the dorsal root ganglia following peripheral nerve injury in rats

Peripheral nerve injury results in sympathetic sprouting around large diameter sensory neurons in the dorsal root ganglia (DRG). The mechanism underlying this pathological phenomenon is not known. Brain-derived neurotrophic factor (BDNF) is up-regulated in large sensory neurons and ensheathing satellite cells following a sciatic nerve injury. In the present study, we investigated the effects of BDNF on the sympathetic sprouting in the DRG, by delivering BDNF antibody or antisense oligodeoxynucleotide to injured DRGs, or by delivering exogenous BDNF to intact DRGs. The sheep antibody to BDNF, characterized by bioassays and dot blots, specifically reacted with BDNF but not other neurotrophins. Noradrenergic fibers were visualized by immunostaining of tyrosine hydroxylase (TH) and quantified by an NIH Imaging program. Two weeks following L5 spinal nerve lesion, a dramatic increase in TH-immunoreactive (-ir) fibres was observed in both ipsi- and contralateral DRGs in normal sheep IgG treated rats. BDNF antibody significantly reduced the sprouting of sympathetic nerves in both ipsi- and contra-lateral DRGs by 67% and 42% respectively. BDNF antisense oligodeoxynucleotide, by inhibiting BDNF synthesis in DRGs, also significantly suppressed the sprouting by 67% and 60% respectively in the ipsi- and contra-lateral DRGs. Delivery of exogenous BDNF into an intact L5 DRGs resulted in an increase in the sprouting by 4.2-fold. Our results clearly indicate that BDNF, synthesized in and secreted from the DRGs, is involved in the sympathetic sprouting in the DRG following the peripheral nerve injury.     

两种术式在缓解恶性输尿管梗阻疗效中的对比研究

目的 探讨恶性输尿管梗阻（malignant ureteral obstruction,MUO）现有的临床治疗方案和经验,讨论恶性输尿管梗阻时使用经皮肾脏穿刺引流（percutaneous nephrostomy,PN）或输尿管支架置入术（ureteral stenting,US）的临床适用范围,明确2种术式在缓解恶性输尿管梗阻时肾功能损伤的有效性。方法 回顾性纳入重庆医科大学附属第一医院泌尿外科2021年1月至2023年5月诊断为恶性输尿管梗阻的患者,严格筛选纳入及排除标准后共有76例患者入组并随机分为PN组（n=22）与US组（n=54）,对患者基本特征及围术期、术后半年随访数据进行病例对照研究以反映肾功能在2组中的差异,采用SPSS 21.0版本对数据进行处理分析。结果 2组患者在性别（P=0.017）、手术侧肾积水程度（P=0.000）的比较,差异有统计学意义。2组患者术前3 d比较尿素氮（P=0.002）、血肌酐（P=0.003）,术后1 d尿素氮（P=0.017）、血肌酐（P=0.005）,差异有统计学意义。术后3 d与术后6个月2组患者在肾功能比较中差异均无统计学意义。结论 恶性输尿管梗阻以宫颈癌多发,其次为位膀胱癌、结直肠癌等。US可选择梗阻或积水较轻、慢性输尿管梗阻、肾功能损伤较轻的患者,可作为缓解输尿管梗阻的首选治疗方案。PN临床常对中至重度肾积水、肾功能损伤较重或者急性肾功能不全的恶性输尿管梗阻患者进行治疗,可作为US失败的替代方案。     

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials

BackgroundHyperphosphatemia and anemia, which are common complications of chronic kidney disease (CKD), can independently contribute to cardiovascular events. Several previous studies have found that the iron-based phosphate binder, ferric citrate (FC), could be beneficial to both hyperphosphatemia and anemia.MethodsRelevant literature from PUBMED, EMBASE, the Cochrane Central Register of Controlled Trials (CCRCT) and MEDLINE databases were searched up to 21 February 2022, in order to conduct a meta-analysis to investigate the efficacy, safety and economic benefits of ferric citrate treatment in CKD patients with hyperphosphatemia and anemia. The meta-analysis was conducted independently by two reviewers using the RevMan software (version 5.3).ResultsIn total, this study included 16 randomized clinical trials (RCT) involving 1754 participants. The meta-analysis showed that ferric citrate could significantly reduce the serum phosphorus in CKD patients compared to the placebo control groups (MD −1.76 mg/dL, 95% CI (−2.78, −0.75); p = 0.0007). In contrast, the difference between ferric citrate treatment and active controls, such as non-iron-based phosphate binders, sevelamer, calcium carbonate, lanthanum carbonate and sodium ferrous citrate, was not statistically significant (MD − 0.09 mg/dL, 95% CI (−0.35, 0.17); p = 0.51). However, ferric citrate could effectively improve hemoglobin levels when compared to the active drug (MD 0.43 g/dL, 95% CI (0.04, 0.82); p = 0.03) and placebo groups (MD 0.39 g/dL, 95% CI (0.04, 0.73); p = 0.03). According to eight studies, ferric citrate was found to be cost-effective treatment in comparison to control drugs. Most of the adverse events (AE) following ferric citrate treatment were mild at most.ConclusionCollectively, our review suggests that iron-based phosphate binder, ferric citrate is an effective and safe treatment option for CKD patients with hyperphosphatemia and anemia. More importantly, this alternative treatment may also less expensive. Nevertheless, more scientific studies are warranted to validate our findings.     

Comparing the efficacy of different intra-articular injections for knee osteoarthritis: A network analysis

Background:The findings on the effectiveness of platelet-rich plasma, ozone, and hyaluronic acid in the treatment of osteoarthritis of the knee are controversial, and the existing original studies and meta-analyses are mostly comparisons of a single joint cavity injection method, lacking direct and indirect comparisons of different drugs in the joint cavity. The lack of direct and indirect comparisons of different drugs in the joint cavity makes it difficult to have a clearer and more comprehensive understanding of joint cavity injection methods. In this study, the efficacy of platelet-rich, ozone, sodium hyaluronate, and combined knee cavity injections were compared directly or indirectly using a reticulated meta-analysis in this field, and the efficacy of treatment measures was ranked to provide more comprehensive and reliable evidence-based clinical evidence for the selection of knee cavity injections in osteoarthritis of the knee.Objective:To compare the effects of platelet-rich plasma, ozone, and sodium glassate injection interventions on the efficacy of osteoarthritis of the knee through reticulated Meta-analysis, and to comprehensively compare the clinical effectiveness of platelet-rich plasma, ozone, and sodium glassate injection joint cavity injection for the treatment of osteoarthritis of the knee.Methods:The PubMed, CBM, CNKI, VIP, and Wan-Fang databases were searched for information on the effectiveness of platelet-rich plasma, ozone, and sodium vitrate injection for the comparative treatment of osteoarthritis of the knee, with a search time frame of each database from the date of creation to July 20, 2021. Two investigators independently screened the literature, extracted data according to inclusion and exclusion criteria, and evaluated the quality of the literature in parallel. Statistical analysis was performed using Stata 16.0 software to compare the differences in the efficacy of each treatment measure using the ratio and 95% confidence interval as effect indicators and to rank the efficacy.Results:Thirty-three RCTs with 7003 patients with osteoarthritis of the knee were included, involving 5 therapeutic measures. Meta-analysis showed that the efficacy of platelet-rich plasma injection was superior to both ozone and hyaluronic acid therapies. Hyaluronic acid+ozone and platelet-rich plasma+hyaluronic acid were both superior to ozone and hyaluronic acid monotherapy. The differences in efficacy between hyaluronic acid and ozone compared with platelet-rich plasma were statistically significant, and the differences in efficacy between the 2 combination therapies (platelet-rich plasma+hyaluronic acid, hyaluronic acid+ozone) and the 3 monotherapies (platelet-rich plasma, ozone, hyaluronic acid) were statistically significant. Platelet-rich plasma+hyaluronic acid, hyaluronic acid+ozone compared with 3 monotherapies (platelet-rich plasma, ozone, hyaluronic acid) were statistically significant, except for the difference in efficacy with platelet-rich plasma, which was not statistically significant, indicating that this platelet-rich plasma+hyaluronic acid and Hyaluronic acid+ozone combination therapy was superior to monotherapy. Also, the efficacy of platelet-rich plasma was better than hyaluronic acid and ozone and the difference was statistically significant, indicating that platelet-rich plasma was more effective than ozone and sodium glass in the treatment of osteoarthritis of the knee in monotherapy.Conclusion:It is believed that in the course of clinical practice, hyaluronic acid+ozone or platelet-rich plasma+hyaluronic acid combination therapy or platelet-rich plasma therapy can be preferred for patients with osteoarthritis of the knee.     

基于人工智能的高血压性脑出血医疗文本信息自动识别系统

目的 构建基于人工智能的高血压性脑出血医疗文本信息自动识别系统,快速识别和分析患者临床信息,高效地输出正确的诊疗方案。方法 基于国内外最新高血压性脑出血诊疗指南,经多位高年资神经外科医生和专业人工智能团队共同讨论,构建基于语言表征模型和专家模块的高血压性脑出血医疗文本信息自动识别及决策系统（即H系统）。随后将收集到的高血压性脑出血病例分为训练集、测试集和验证集,以数据库中病例的真实治疗方案为金标准,先总体评价H系统的准确性,再将其与神经外科医生进行对比,分析H系统的判读效率。结果 在测试集中,H系统所输出的治疗方案的准确率为94.0%（91.5%~96.5%）,特异度为91.8%（86.3%~97.3%）,灵敏度为95.5%（89.3%~98.2%）,曲线下面积（area under the curve,AUC）值为0.936（0.922~0.950）（P=0.000）;在验证集中,H系统所输出的治疗方案的准确率为93.3%（89.5%~97.1%）,特异度为 89.9%（83.4%~96.4%）,灵敏度为95.8%（92.3%~99.3%）,AUC值为0.928（0.891~0.966）（P=0.000）。在处理同样的70例病例时,H系统用时（334.60±4.46）s,而神经外科医生用时（12 550.28±95.45）s;在50 min内,H系统处理的病例数为（383±3）例,而神经外科医生处理的病例数为（11±4）例。结论 本研究所构建的H系统能够对高血压性脑出血患者的急诊病例进行自动识别和分析,并快速输出准确的诊疗方案,可协助医生对高血压脑出血进行急诊诊疗。